Topical Itraconazole in the Treatment of Basal Cell Carcinoma

Inclusion Criteria:

* Participants must be over the age of 18 years
* Male
* Women who do not have child-bearing potential (history of hysterectomy, post-menopausal)
* Have a biopsy confirmed BCC that measures at least 6mm in size at the time of the initial evaluation (visit #1);
* Participant must be willing and comply with the requirements of the protocol;
* Participant must have the ability to understand and communicate with the investigator;
* Participant must provide informed consent.

Exclusion Criteria:

* Subject with significant congestive heart failure (CHF) or history of CHF, chronic renal failure, hepatic failure, neuropathy
* Subject with current skin diseases that the investigator feels is not safe for study participation including but not limited to severe atopic dermatitis, cutaneous T-cell lymphoma, erythroderma;
* Subjects on systemic medications known to affect the Hedgehog pathway (see Appendix I)
* Subjects on cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine, dofetilide, triazolam, methadone, levacetylmethadol (levomethadyl), lovastatin, simvastatin, dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), cisapride, pimozide, methadone, levacetylmethadol (levomethadyl), quinidine
* Subjects with history of hypersensitivity to azoles
* Subjects with Gorlin syndrome
* Subjects on chronic immunosuppression, or who have a history of compromised immune function (e.g. history of or current malignancy other than BCC/squamous cell skin cancers)
* Subjects who do not speak English or have difficulty hearing or are otherwise impaired for providing informed consent and communicating with the investigator;
* Subjects with a history of keloids or excessive scarring;
* Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum
* Women of child-bearing age/potential and/or able to conceive